FDA Accuses uniQure of Data Manipulation for AMT-130; Legal Action Intensifies

Key Facts

1The FDA reportedly accused uniQure of pushing 'distorted' and 'manipulated' data for its AMT-130 drug.

2Law firm Hagens Berman is updating its investigation into a securities class action against the company.

3Federal health officials reportedly characterized the AMT-130 drug as 'failed'.

The U.S. Food and Drug Administration (FDA) has reportedly issued a severe rebuke against uniQure N.V., accusing the biotechnology firm of presenting "distorted" and "manipulated" clinical data. The allegations center on the company's experimental drug AMT-130, which federal health officials have characterized as a "failed" treatment. In response to these developments, the law firm Hagens Berman has announced an update to its ongoing investigation into a securities class action lawsuit against the company. The investigation seeks to determine whether uniQure misled investors regarding the efficacy and regulatory status of its key drug candidate. This regulatory scrutiny represents a significant blow to the company's credibility and its future prospects in the gene therapy market. Market analysts expect these accusations to exert substantial downward pressure on the stock as legal and regulatory risks escalate.